-
公开(公告)号：EP3549932B1
公开(公告)日：2020-09-30
申请号：EP17881314.3
申请日：2017-12-13
发明人： CHEN, Minhua , ZHANG, Yanfeng , ZOU, Po , WANG, Jinqiu , ZHANG, Xiaoyu
IPC分类号： C07D213/65 , A61K31/44 , A61P7/00 , C07D213/81
-
公开(公告)号：EP3508481A1
公开(公告)日：2019-07-10
申请号：EP17850293.6
申请日：2017-09-14
发明人： CHEN, Minhua , ZHANG, Yanfeng , ZHAI, Xiaoting , YAN, Kaiqiang , YANG, Chaohui , ZHANG, Xiaoyu
IPC分类号： C07D271/06 , A61K31/4245 , A61P1/00 , A61P1/04 , A61P37/02 , A61P25/00
摘要： The present disclosure relates to crystalline form CS3 of ozanimod hydrochloride which can be used for treating autoimmune diseases, particularly used for preparing drugs for treating multiple sclerosis and ulcerative colitis and preparation method thereof.
-
公开(公告)号：EP3763703A2
公开(公告)日：2021-01-13
申请号：EP20190094.1
申请日：2017-12-13
发明人： CHEN, Minhua , ZHANG, Yanfeng , ZOU, Po , WANG, Jinqiu , ZHANG, Xiaoyu
IPC分类号： C07D213/65 , A61K31/44 , A61P7/00 , C07D213/81
摘要： The present disclosure relates to novel crystalline forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl] amino} acetic acid and processes for preparation and uses thereof. Crystalline form CS1, form CS2 and form CS8 of the present disclosure can be used for preparing drugs treating anemia, which providing new choices for preparing drugs of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl] amino} acetic acid, and having very important value for drug development.
-
4.发明公开
公开(公告)号：EP3470400A1
公开(公告)日：2019-04-17
申请号：EP17812728.8
申请日：2017-06-14
发明人： CHEN, Minhua , ZHANG, Yanfeng , ZHAI, Xiaoting , YAN, Kaiqiang , YANG, Chaohui , ZHANG, Xiaoyu
IPC分类号： C07D271/06 , A61K31/4245 , A61P37/00
摘要： The present disclosure is directed to novel crystalline forms of ozanimod and ozanimod hydrochloride, as well as preparation method thereof. Said crystalline forms of ozanimod and ozanimod hydrochloride can be used for treating autoimmune diseases, particularly used for preparing drugs for treating multiple sclerosis and ulcerative colitis. The crystalline forms of the present disclosure have one or more advantages in solubility, melting point, stability, dissolution, bioavailability and processability and provide new and better choices for the preparation of ozanimod drug product, and are very valuable for drug development.
-
公开(公告)号：EP3473623B1
公开(公告)日：2020-07-15
申请号：EP17819332.2
申请日：2017-06-29
发明人： CHEN, Minhua , ZHANG, Yanfeng , ZOU, Po , LIU, Kai , WANG, Jinqiu , ZHANG, Xiaoyu
IPC分类号： C07D455/08 , A61K31/473 , A61P25/14 , C07D455/06
-
公开(公告)号：EP3502100A1
公开(公告)日：2019-06-26
申请号：EP17841121.1
申请日：2017-08-18
发明人： CHEN, Minhua , ZHANG, Yanfeng , ZHAI, Xiaoting , YAN, Kaiqiang , YANG, Chaohui , ZHANG, Xiaoyu
IPC分类号： C07D271/06 , A61K31/4245 , A61P1/00 , A61P1/04 , A61P37/02 , A61P25/00
摘要： The present disclosure relates to novel crystalline forms of ozanimod and preparation method thereof. The provided crystalline forms of ozanimod comprise crystalline form CS9, crystalline form CS10 and crystalline form CS11, and can be used for treating autoimmune diseases, particularly used for preparing drugs for treating multiple sclerosis and ulcerative colitis. The crystalline forms of the present disclosure have one or more advantages in solubility, stability, hygroscopicity and processability and provide new and better choices for the preparation of ozanimod drug product, and are very valuable for drug development.
-
7.发明公开
公开(公告)号：EP3495352A1
公开(公告)日：2019-06-12
申请号：EP17842980.9
申请日：2017-08-25
发明人： CHEN, Minhua , ZHANG, Yanfeng , LI, Jiaoyang , YAN, Kaiqiang , LIU, Qiyue , ZHANG, Xiaoyu
IPC分类号： C07D231/14 , A61K31/4155 , A61P35/00
摘要： The present disclosure relates to novel crystalline forms of an androgen receptor antagonist drug (ODM-201 represented by formula (1)), preparation method thereof and use thereof. The crystalline form B or the crystalline form C of ODM-201 provided by the present disclosure has low hygroscopicity, good stability, high solubility, excellent flowability, optimal particle size with uniform distribution, which provides a new choice for the preparation of drugs containing ODM-201 and is of great value for drug development.
-
公开(公告)号：EP3473623A1
公开(公告)日：2019-04-24
申请号：EP17819332.2
申请日：2017-06-29
发明人： CHEN, Minhua , ZHANG, Yanfeng , ZOU, Po , LIU, Kai , WANG, Jinqiu , ZHANG, Xiaoyu
IPC分类号： C07D455/08 , A61K31/473 , A61P25/14
摘要： The present disclosure relates to novel crystalline forms of NBI-98854 (as shown in formula I), preparation process and use thereof. The crystalline forms of NBI-98854 provided by the present disclosure, named as Form CS1 and Form CS2, can be used for preparing drug product treating tardive dyskinesia. The crystalline forms of NBI-98854 provided by the present disclosure have pharmaceutically acceptable solubility and hygroscopicity, good stability and are stable during storage, thereby avoiding changes in drug solubility, dissolution rate, bioavailability and efficacy due to polymorph transformation. This provides a new and better choice for the preparation of drug product containing NBI-98854, which has significant value for future drug development.
-
9.发明公开
公开(公告)号：EP3466958A1
公开(公告)日：2019-04-10
申请号：EP17802197.8
申请日：2017-05-25
发明人： CHEN, Minhua , ZHANG, Yanfeng , ZOU, Po , LIU, Kai , ZHANG, Xiaoyu
IPC分类号： C07H15/14 , C07H1/06 , A61K31/7028 , A61P3/10
摘要： The present disclosure relates to novel crystalline forms of a sodium-glucose co-transporter inhibitor drug (Sotagliflozin), processes for preparation and use thereof. The present disclosure also relates to pharmaceutical composition comprises novel crystalline forms of Sotagliflozin and use of novel crystalline forms and pharmaceutical composition of Sotagliflozin for preparing drugs for treating diseases. The crystalline forms provided by the present disclosure have advantages of good stability, relatively low hygroscopicity, suitability for process development and post-treatment, simple processes for preparation, low cost, and has significant value for future drug optimization and development.
-
10.发明公开
公开(公告)号：EP3701951A1
公开(公告)日：2020-09-02
申请号：EP18869512.6
申请日：2018-10-22
发明人： CHEN, Minhua , ZHANG, Yanfeng , ZHANG, Jing , ZHANG, Xiaoyu , LIU, Kai
IPC分类号： A61K31/567 , A61P5/36 , A61P15/00
摘要： The present disclosure relates to novel crystalline forms of compound I and processes for preparation thereof. The present disclosure also relates to pharmaceutical composition containing crystalline forms, and use of crystalline forms for preparing drugs containing selective progesterone receptor modulator, and use of crystalline forms for preparing drugs treating uterine fibroids and/or endometriosis. The crystalline forms of the present disclosure have one or more improved properties compared with prior art and have significant values for future drug optimization and development.
-
-
-
-
-
-
-
-
-
搜索结果
19 条记录 (耗时 0.016 秒)
